A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
- Conditions
- Non Small Cell Lung Cancer MetastaticALK Gene Mutation
- Interventions
- Registration Number
- NCT06378892
- Lead Sponsor
- Centro di Riferimento Oncologico - Aviano
- Brief Summary
This study aims to evaluate the activity and safety of the combination of platinum-pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression on Lorlatinib. Platinum-pemetrexed based chemotherapy plus Lorlatinib will be administered for an induction phase of four cycles. Subsequently, patients with response or stability of disease at radiological assessment will start the maintenance phase with pemetrexed-Lorlatinib in 21-day cycles until progression, unacceptable toxicity, death, or withdrawal of consent.
- Detailed Description
This is a multicentre, phase II, interventional, prospective, single arm, non-randomised study focused on ALK+ NSCLC with extracranial progression on Lorlatinib.Treatment phase include the period starting from cycle 1 day 1 visit to discontinuation of study therapy and consists of two phases: induction phase and maintenance phase. Platinum-pemetrexed based chemotherapy plus Lorlatinib will be administered for an induction phase of four cycles. Subsequently, patients with response or stability of disease at radiological assessment will start the maintenance phase with pemetrexed-Lorlatinib in 21-day cycles until progression, unacceptable toxicity, death, or withdrawal of consent.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 45
- Histologically or cytologically confirmed diagnosis of stage IV ALK positive NSCLC.
- Patients must be in progression extracranially on Lorlatinib; Lorlatinib may be in first- or further-line, without limitations regarding previously received therapies.
- Age at the time of signing the informed consent at least 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Patients must have measurable disease according to RECIST 1.1 by computed tomography (CT) and magnetic resonance imaging (MRI).
- Radiologically confirmed multiple extracranial progression on Lorlatinib without progression in the central nervous system (CNS) defined as absence of CNS metastasis or CNS metastasis stable on Lorlatinib and/or stereotactic brain irradiation (SBRT).
- Adequate organ function (kidney, bone marrow and liver).
- Estimated life expectancy of at least 3 months irrespective of the diagnosis of ALK+ NSCLC.
- For women of childbearing potential and males with partners of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of study drugs.
Key
- Known hypersensitivity reaction to one of the compounds or substances used in this protocol.
- Diagnosis of any secondary malignancy within the last 3 years except for: adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, definitively treated nonmetastatic prostate cancer or patients with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.
- Patients deemed unsuitable by the investigator for treatment of chemo-Lorlatinib combination.
- Presence of toxicities contraindicating the continuation of therapy with Lorlatinib.
- Concomitant use of potent CYP3A4/5 inducers.
Other inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Lorlatinib Lorlatinib Lorlatinib 100mg once daily. Carboplatin AUC 5 or Cisplatin 75 mg/m\^2 for an induction phase of four cycles. Pemetrexed 500 mg/m\^2 during the maintenance phase.
- Primary Outcome Measures
Name Time Method Compare Progression Free Survival between patients treated with Pemetrexed (PT)/pem-based chemotherapy plus Lorlatinib after Lorlatinib versus retrospective data of 3,2 months for patients treated with PT/pem-based chemotherapy after Lorlatinib. Up to 60 months PFS defined as the time from study enrollment to the first documented disease progression or death due to any cause, whichever occurs first.
- Secondary Outcome Measures
Name Time Method Intracranial Progression Free Survival (PFS) in patients treated with PT/pem-based chemotherapy plus Lorlatinib after Lorlatinib. Up to 60 months Intracranial PFS defined as time from study enrollment until CNS disease progression or death from any cause.
Overall survival (OS) in patients treated with PT/pem-based chemotherapy plus Lorlatinib after Lorlatinib progression Up to 60 months OS is defined as the time from study enrollment until death from any cause.
Describe the safety of PT/pem-based chemotherapy plus Lorlatinib combination Up to 60 months Frequency and severity of adverse events graded according to the CTCAE version 5.0.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (9)
Azienda Ospedaliera di Perugia
🇮🇹Perugia, Italy
Centro di Riferimento Oncologico (CRO) IRCCS
🇮🇹Aviano, Italy
Azienda Ospedaliero-Universitaria Careggi Oncologia Medica
🇮🇹Firenze, Italy
Azienda USL Toscana Nord Ovest Oncologia Medica, Ospedale Versilia
🇮🇹Lido Di Camaiore, Italy
Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino amadori"
🇮🇹Meldola, Italy
Fondazione IRCCS San Gerardo dei Tintori
🇮🇹Monza, Italy
IOV Istituto Oncologico Veneto IRCCS
🇮🇹Padova, Italy
Azienda Ospedaliero-Universitaria di Parma
🇮🇹Parma, Italy
Azienda Sanitaria Universitaria Friuli Centrale (ASU FC)
🇮🇹Udine, Italy